Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TomaGold Borehole EM Survey Confirms Berrigan Deep Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Tempest Therpeutics Inc TPST

Healthcare Biotechnology
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule... see more

Current News (NDAQ:TPST)

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

GlobeNewswire 2 days ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

GlobeNewswire January 20, 2026

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 26, 2025

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 25, 2025

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

GlobeNewswire November 19, 2025

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 5, 2025

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 11, 2025

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

GlobeNewswire June 30, 2025

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

GlobeNewswire June 11, 2025
View More News ››

Opinion & Analysis (NDAQ:TPST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TPST)

Using technical analysis for this stock.

It is signalling strength to the upside today,so good luck to all shareholders
coolfooldumbguy - June 9, 2025

What news to come?

Good week 
Tulsa123 - December 15, 2024

Good choice?

Interested in owning stocks. What do you suggest? Tx
Tulsa123 - November 10, 2024

Tempest Therapeutics, Inc. (NASDAQ:TPST): A Promising Oncolo

http://beyondspx.com/2024/08/01/tempest-therapeutics-inc-nasdaqtpst-a-promising-oncology-pipeline-backed-by-solid-financials/
MikeTester - August 2, 2024

This company is so tight it squeaks , 22 million SO .

Moose Jaw 
Galaxym31 - April 3, 2024

What is going on with this volume ?

.
Galaxym31 - April 1, 2024
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts